Although the relationship between treatment with TNF inhibitors and MS has been established, it is currently unclear whether these pharmacological agents trigger the demyelinating disease or rather exacerbate an asymptomatic underlying neurologic inflammation. Here, TNF is linked to myeloid sarcoma.